MADRIGAL PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.3 USD | -0.30% |
|
-10.54% | -11.14% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 76.72M | Sales 2025 * | 360M | Capitalization | 4.41B |
|---|---|---|---|---|---|
| Net income 2024 * | -570M | Net income 2025 * | -405M | EV / Sales 2024 * | 57 x |
| Net cash position 2024 * | 35.16M | Net Debt 2025 * | 175M | EV / Sales 2025 * | 12.7 x |
| P/E ratio 2024 * |
-7.48
x | P/E ratio 2025 * |
-10.9
x | Employees | 376 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Madrigal Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -1.23% | ||
| 1 week | -10.85% | ||
| Current month | +0.44% | ||
| 1 month | -16.25% | ||
| 3 months | -5.28% | ||
| 6 months | +47.59% | ||
| Current year | -11.44% |
1 week
200.08
236.65
1 month
189.00248.63
Current year
168.25299.98
1 year
119.76302.68
3 years
52.33322.67
5 years
52.33322.67
10 years
6.60325.98
| Managers | Title | Age | Since |
|---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 205.6 | -0.65% | 72 925 |
| 24-05-09 | 206.9 | -0.54% | 359,475 |
| 24-05-08 | 208 | -4.55% | 690,496 |
| 24-05-07 | 218 | -7.48% | 780,739 |
| 24-05-06 | 235.6 | +2.49% | 423,461 |
Delayed Quote Nasdaq, May 10, 2024 at 10:48 am EDT
More quotes
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
206.9
USD
Average target price
364.3
USD
Spread / Average Target
+76.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.44% | 4.41B | |
| +2.76% | 108B | |
| +11.14% | 104B | |
| +1.48% | 22.33B | |
| -11.94% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.12% | 17.64B | |
| +5.40% | 14.05B | |
| +35.04% | 12.51B |
- Stock Market
- Equities
- MDGL Stock